drugset / Trial / NCT01584843
Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
RandomizedParallel-groupSingle-blindTreatment
Summary
Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820 compared with non-treatment in patients with strabismus based on angles of strabismus in the primary position.
Timeline
- Start
- 2012-05
- Primary completion
- 2013-07
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GSK1358820 | Protein / enzyme biologic | 1.25 iu | Intramuscular |
| Comparator | GSK1358820 | Protein / enzyme biologic | 2.5 iu | Intramuscular |
| Comparator | GSK1358820 | Protein / enzyme biologic | 5 iu | Intramuscular |